Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-04T21:19:19.375Z Has data issue: false hasContentIssue false

Atomoxetine improved response inhibition in adults with ADHD

Published online by Cambridge University Press:  16 April 2020

N. del Campo
Affiliation:
Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
S.R. Chamberlain
Affiliation:
Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
J. Dowson
Affiliation:
Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
U. Muller
Affiliation:
Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
L. Clark
Affiliation:
Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
T.W. Robbins
Affiliation:
Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
B.J. Sahakian
Affiliation:
Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Atomoxetine, a highly selective noradrenaline reuptake inhibitor, shows efficacy in the treatment of ADHD. Despite evidence that atomoxetine improved inhibitory control in animals and healthy volunteers, studies had yet to explore short-term cognitive effects in patients with ADHD.

Method:

The cognitive effects of a single oral dose of atomoxetine (60mg) were evaluated in n=22 adults with DSM-IV ADHD, using a within-subject placebo-controlled double-blind design. Assessment included the stop-signal test and Rapid Visual Information Processing test from the Cambridge Neuropsychological Test Automated Battery (CANTAB). Cardiovascular responses were monitored. Normative cognitive data from 20 healthy volunteers were collected for comparison.

Results:

Atomoxetine was associated with shorter stop-signal reaction times (p<0.05) and lower numbers of commission errors (p<0.05) on the sustained attention task in the ADHD patients.

Conclusions:

These findings suggest that atomoxetine exerts beneficial effects on aspects of inhibitory control in ADHD, which may belie the efficacy of this medication in the treatment of impulsive features of the disorder. These findings also have potential clinical implications for other impulse dysregulation disorders such as trichotillomania and Tourette's Syndrome.

Type
Poster Session 2: Organic Mental Disorders and Memory and Cognitive Dysfunctions
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.